drugset / Trial / NCT03829566
Autologous Transplant To End NMO Spectrum Disorder
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term remission.
Timeline
- Start
- 2019-11
- Primary completion
- 2025-01
- Completion
- 2025-11-28
Outcome
Outcome not reported
Stopped: “Discontinued by Investigator”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Stem Cells | Cell therapy | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | G-CSF | Protein / enzyme biologic | — | — |
| Background | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | — |
| Background | Methylprednisolone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | rATG | Protein / enzyme biologic | — | — |